Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04895162 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-04895162 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04895162 | DRUG | Tablets, 300 mg, single, 1 day |
| Placebo | DRUG | Tablets, twice a day, 14 days |
Inclusion Criteria: 1. Healthy male and/or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and puls...
PF-04895162 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
PF-04895162 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-04895162 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
PF-04895162 has been evaluated in one completed Phase 1 trial, NCT01691274, titled "A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162." The trial enrolled 10 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
No. PF-04895162 is an investigational drug and has not been approved by the FDA. It has completed only a single Phase 1 trial involving 10 healthy volunteers, so it remains in early clinical development.